Literature DB >> 22942654

P16 protein expression in primary cutaneous melanoma with positive and negative lymph node biopsies: Particular aspects of a study performed at the Hospital de Clinicas de Porto Alegre, Brazil.

Jac Fauri1, F Ricardi, Es Diehl, A Cartell, R Furian, L Bakos, Mi Edelweiss.   

Abstract

BACKGROUND: Cutaneous melanoma dermal invasion, identified through measurement of maximum tumour thickness and sentinel lymph node (SLN) biopsy, is important to establish melanoma prognosis and progression. P16 protein expression has been shown to be a predictive factor for melanoma evolution and prognosis.
OBJECTIVE: To investigate p16 protein expression in cutaneous melanomas with and without SLN metastasis. PATIENTS AND METHODS: Sixty-seven paraffin-embedded cutaneous melanoma specimens of patients who had undergone SLN investigation were evaluated from 1995 to 2007. SLN biopsy was negative for metastasis in 34 of these patients (controls); in the remaining 33 patients, SLN biopsy was positive (cases). The expression of p16 protein in the primary tumour was measured using an immunohistochemical assay. The samples were classified according to their nuclear expression.
RESULTS: P16 nuclear expression was absent in 14 cases and in 15 controls; P=0.812. There was no statistically significant difference in p16 nuclear expression between cases and controls.
CONCLUSIONS: The present study does not support the findings of other studies that suggest p16 protein expression is important in the prognosis of cutaneous melanoma.

Entities:  

Keywords:  Cutaneous melanoma; Immunohistochemistry; Metastasis; Sentinel lymph node; p16

Year:  2011        PMID: 22942654      PMCID: PMC3269325          DOI: 10.1177/229255031101900313

Source DB:  PubMed          Journal:  Can J Plast Surg        ISSN: 1195-2199


  17 in total

1.  An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma.

Authors:  J S Chana; R Grover; G D Wilson; D A Hudson; M Forders; R Sanders; A O Grobbelaar
Journal:  Br J Plast Surg       Date:  2000-01

2.  False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology.

Authors:  Rooshdiya Z Karim; Richard A Scolyer; Wei Li; Vivian S K Yee; J Gregory McKinnon; Ling-Xi L Li; Roger F Uren; Stella Lam; Alison Beavis; Michael Dawson; Philip Doble; Dave S B Hoon; John F Thompson
Journal:  Ann Surg       Date:  2008-06       Impact factor: 12.969

3.  The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

Authors:  M G Statius Muller; P A van Leeuwen; E S de Lange-De Klerk; P J van Diest; R Pijpers; C C Ferwerda; R J Vuylsteke; S Meijer
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

4.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

5.  p16 expression in primary malignant melanoma is associated with prognosis and lymph node status.

Authors:  Daniela Mihic-Probst; Christian D Mnich; Patrick A Oberholzer; Burkhardt Seifert; Bernd Sasse; Holger Moch; Reinhard Dummer
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

6.  Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.

Authors:  O Straume; L Sviland; L A Akslen
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.

Authors:  Oddbjørn Straume; Johanna Smeds; Rajiv Kumar; Kari Hemminki; Lars Andreas Akslen
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

8.  Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.

Authors:  Carlo Riccardo Rossi; Gian Luca De Salvo; Elena Bonandini; Simone Mocellin; Mirto Foletto; Sandro Pasquali; Pierluigi Pilati; Mario Lise; Donato Nitti; Elisa Rizzo; Maria Cristina Montesco
Journal:  Ann Surg Oncol       Date:  2008-04       Impact factor: 5.344

Review 9.  Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma.

Authors:  M B Lens; M Dawes
Journal:  Br J Dermatol       Date:  2004-02       Impact factor: 9.302

10.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

Authors:  Soledad R Alonso; Pablo Ortiz; Marina Pollán; Beatriz Pérez-Gómez; Lydia Sánchez; Ma Jesús Acuña; Raquel Pajares; Francisco J Martínez-Tello; Carlos M Hortelano; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.